Evaluation of neuroendocrine markers in renal cell carcinoma

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Ronkainen, Hanna ^a   Soini, Ylermi ^b   Vaarala, Markku H ^a   Kauppila, Saila ^a   Hirvikoski, Pasi ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; ENOLASE; NCAM1 PROTEIN, HUMAN; SEROTONIN; SYNAPTOPHYSIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHEMISTRY; CHI SQUARE DISTRIBUTION; EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; CHROMOGRANIN A; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEROTONIN; SURVIVAL RATE; SYNAPTOPHYSIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951985409     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-28     Document Type: Article

References (24)

1. Nesland JM, Holm R, Johannessen JV, Gould VE. Neuroendocrine differentiation in breast lesions. Pathol Res Pract 1988, 183:214-221.
2. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009, 1:148-162. 2776313, 19956427.
3. IARC Tumours of the Urinary System and Male Genital Organs. 2004, IARC Press, Lyon, IARC.
4. Viallet J, Ihde DC. Small cell carcinoma of the lung: clinical and biologic aspects. Crit Rev Oncol Hematol 1991, 11:109-135. 10.1016/1040-8428(91)90002-T, 1657028.
5. Dahabreh J, Stathopoulos GP, Koutantos J, Rigatos S. Lung carcinoid tumor biology: treatment and survival. Oncol Rep 2009, 21:757-760.
6. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004, 59:328-336. 10.1002/pros.10374, 15042609.
7. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 2002, 168:1204-1211. 10.1016/S0022-5347(05)64626-5, 12187268.
8. Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH. The role of serotonin in tumour growth (review). Oncol Rep 2005, 14:1593-1597.
9. Julius D, Livelli TJ, Jessell TM, Axel R. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 1989, 244:1057-1062. 10.1126/science.2727693, 2727693.
10. Vicaut E, Laemmel E, Stucker O. Impact of serotonin on tumour growth. Ann Med 2000, 32:187-194. 10.3109/07853890008998826, 10821326.
11. Jungwirth N, Haeberle L, Schrott KM, Wullich B, Krause FS. Serotonin used as prognostic marker of urological tumors. World J Urol 2008, 26:499-504. 10.1007/s00345-008-0285-9, 18581119.
12. Edgren M, Stridsberg M, Kalknar KM, Nilsson S. Neuroendocrine markers; chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell carcinoma. Anticancer Res 1996, 16:3871-3874.
13. Dabbs DJ. Diagnostic Immunohistochemistry. 2006, Elsevier, Philadelphia.
14. Daniel L, Bouvier C, Chetaille B, Gouvernet J, Luccioni A, Rossi D, Lechevallier E, Muracciole X, Coulange C, Figarella-Branger D. Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol 2003, 34:528-532. 10.1016/S0046-8177(03)00178-3, 12827605.
15. Erickson LA, Lloyd RV. Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol 2004, 11:175-189. 10.1097/01.pap.0000131824.77317.a7, 15220821.
16. Yaman O, Baltaci S, Arikan N, Ozdiler E, Gogus O, Muftuoglu YZ. Serum neuron specific enolase: can it be a tumour marker for renal cell carcinoma?. Int Urol Nephrol 1996, 28:207-210. 10.1007/BF02550862, 8836790.
17. Rasmuson T, Grankvist K, Roos G, Ljungberg B. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase. Acta Oncol 1999, 38:623-628. 10.1080/028418699431221, 10427952.
18. UICC TNM Classification of Malignant Tumours. 1999, Wiley & Sons, New York, 6, UICC.
19. Taraif SH, Deavers MT, Malpica A, Silva EG. The Significance of Neuroendocrine Expression in Undifferentiated Carcinoma of the Endometrium. Int J Gynecol Pathol 2009, 28:142-7. 10.1097/PGP.0b013e3181895539, 19188820.
20. Moinfar F. Essentials of diagnostic breast pathology. 2007, Springer, Berlin.
21. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 1967, 215:58-59. 10.1038/215058a0, 6053402.
22. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003, 348:1134-1149. 10.1056/NEJMra021405, 12646671.
23. Gould VE, Wiedenmann B, Lee I, Schwechheimer K, Dockhorn-Dworniczak B, Radosevich JA, Moll R, Franke WW. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 1987, 126:243-257. 1899573, 3103452.
24. Wiedenmann B, Huttner WB. Synaptophysin and chromogranins/secretogranins--widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol 1989, 58:95-121. 10.1007/BF02890062, 2575822.